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Abstract
Background Patients with uncontrolled type 2 diabetes
mellitus (T2DM) are a priority group for intensified therapy
without weight gain and with low risk of hypoglycaemia.
Objective This study evaluates the cost effectiveness of
insulin degludec plus liraglutide (IDegLira, Xultophy)
compared with six potential intensification treatment options
for patientswithT2DM that is uncontrolledwith basal insulin.
Methods The Swedish Institute for Health Economics (IHE)
Cohort Model of Type 2 Diabetes was used with Swedish
input data, a 40-year time frame and a societal perspective.
The comparators for treatment intensification included
insulin glargine, neutral protamine Hagedorn (NPH) insulin,
insulin aspart plus either glargine or NPH, and liraglutide
plus either glargine or NPH. Clinical data for all compara-
tors (except NPH insulin) were based on an indirect treat-
ment comparison of several studies. Prices were obtained
from the 2014 Swedish Dental and Pharmaceutical Benefits
Agency (Tandva˚rds- och la¨kemedelsfo¨rma˚nsverket [TLV])
database, and utility values were obtained from published
studies. Sensitivity analyses were undertaken.
Results Overall incremental cost-effectiveness ratios
(ICER) were Swedish krona (SEK) 70,000 or lower per
quality-adjusted life-year (QALY). IDegLira compared
with intensified basal insulin showed an ICER of SEK
28,000 per QALY versus insulin glargine, SEK70,000 per
QALY versus NPH insulin and SEK 60,000 per QALY
versus NPH insulin plus liraglutide. IDegLira was domi-
nant over insulin glargine plus liraglutide and insulin aspart
plus insulin glargine or NPH insulin. Results were driven
by the difference in glycated haemoglobin (HbA1c)
reduction between treatments, as confirmed by sensitivity
analyses.
Conclusions IDegLira is estimated to be a cost-effective
treatment in Sweden compared with commonly used
intensification treatments for patients with T2DM uncon-
trolled with basal insulin.
Key Points for Decision Makers
Insulin degludec plus liraglutide (IDegLira) is
estimated to be a cost-effective treatment for patients
with type 2 diabetes mellitus compared with other
commonly available therapies in Sweden.
These analyses show glycaemic control is the main
driver of differences in cost effectiveness between
treatments.
1 Introduction
The overall therapeutic goal for patients with type 2 dia-
betes mellitus (T2DM) is to prevent acute and long-term
complications while maintaining quality of life. Glycaemic
control, expressed as glycated haemoglobin (HbA1c), is a
key therapeutic target because elevated HbA1c levels are
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associated with an increased risk of complications and
mortality and thus increased healthcare costs [1]. An
HbA1c of \52 mmol/mol (6.9%) is a commonly stated
target value [2–4]; however, in 2015, only half of the
patient population with T2DM in Sweden achieved this
target [5]. Swedish patients with HbA1c [73 mmol/mol
(8.8%) are considered a priority group for intensified
treatment, both by the Swedish National Diabetes Register
(NDR) and the Swedish National Board of Health and
Welfare [6, 7].
Common barriers to achieving glycaemic control
include hypoglycaemia, weight gain and adherence to
treatment. Hypoglycaemia can cause burdensome symp-
toms such as dizziness, headache, anxiety, lack of con-
centration and confusion [2, 8], which can affect the ability
to work and carry out daily activities [9]. In Sweden,
insulin-treated patients with T2DM have been reported to
experience an average of one episode of hypoglycaemia
every 2 weeks [10–12]. Severe hypoglycaemia may, in rare
cases, lead to loss of consciousness or death [2, 8] and can
incur high societal costs [13]. Weight gain is perceived as
another barrier to achieving glycaemic targets [14] as it
increases the risk of cardiovascular disease, mortality and
impaired quality of life [15], which also lead to increased
healthcare costs [16].
Simplified insulin treatment regimens may improve
glycaemic control since the number of daily injections has
been reported to be a major issue in adherence to diabetes
treatments [17]. Treatment complexity is a common reason
why patients and physicians are reluctant to intensify
treatment from basal insulin alone to basal–bolus, even
when such intensification is indicated for achieving gly-
caemic targets [18]. Basal–bolus treatment also requires
frequent blood glucose tests, which may impact on treat-
ment adherence [19].
Swedish guidelines currently recommend an intermedi-
ate-acting basal human insulin (neutral protamine Hage-
dorn [NPH] insulin; Insuman Basal) to be routinely
prescribed in T2DM, with long-acting insulin analogs
(such as insulin glargine, Lantus; insulin detemir,
Levemir; insulin degludec, Tresiba) offered as second-
line treatment or when patients experience repeated
hyperglycaemic episodes [20]. Furthermore, guidelines
published by the American Diabetes Association and the
European Association for the Study of Diabetes also rec-
ommend that a basal–bolus regimen be offered to patients
who do not adequately respond to glucagon-like peptide
(GLP)-1 agonists added to basal insulin [21].
Insulin degludec plus liraglutide (IDegLira; Xultophy)
is a new treatment for use in combination with oral glu-
cose-lowering agents when these alone or combined with a
GLP-1 receptor agonist or basal insulin do not provide
adequate glycaemic control for patients with T2DM. It
combines basal insulin (insulin degludec) and a GLP-1
receptor analogue (liraglutide), both of which are already
included in the Swedish National reimbursement
scheme for use in T2DM.
The aim of this study was to evaluate the cost effec-
tiveness of IDegLira compared with insulin glargine
(Lantus) and NPH insulin (Insuman Basal) as basal
insulins, insulin aspart (NovoRapid) added to either
insulin glargine or NPH insulin, and liraglutide (Victoza)
added to either insulin glargine or NPH insulin, for patients
with T2DM whose HbA1c is uncontrolled despite basal
insulin treatment.
2 Materials and Methods
The Swedish Institute for Health Economics (IHE) Cohort
Model of Type 2 Diabetes was used for the cost-effec-
tiveness analyses, with Swedish data for development of
complications, costs and patient benefits associated with
T2DM. A 40-year perspective was used to capture all costs
and effects for the remainder of the patient’s life (a societal
perspective, including healthcare costs and productivity
losses, was used in the main analysis, and a healthcare
perspective was used in the sensitivity analysis). A 3%
discount rate was applied to costs and effects as per
guidelines by the Swedish Dental and Pharmaceutical
Benefits Agency (Tandva˚rds- and la¨kemedelsfo¨rma˚nsver-
ket [TLV]) [22]. Outcomes measured in cost per quality-
adjusted life-years (QALYs) were compared with the
thresholds set out by the Swedish National Board of Health
and Welfare to determine whether an intervention was cost
effective. This board consider a cost per QALY below
Swedish krona (SEK)100,000 as low, whereas incremental
cost-effectiveness ratios (ICERs) between SEK100,000 and
500,000 per QALY are deemed as moderate [23]. Any
assumptions used within the model were made because
data were lacking; assumptions are intended to be conser-
vative to maintain objectivity.
2.1 Model Structure
The model was developed by the Swedish IHE and used
Markov health states to capture key microvascular and
macrovascular complications and early T2DM-related
death. A schematic overview of the model is presented in
Fig. S1 in the Electronic Supplementary Material (ESM). It
was designed in Microsoft Excel 2013 using Visual Basic
for Applications and has been externally validated as
described in Lundqvist et al. [24]. The model includes
multiple variables such as cohort baseline characteristics
(e.g. age, sex, ethnicity, biomarkers and complications),
unit costs, utility weights and choice of risk equations, with
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a treatment algorithm linked to HbA1c defined by the user
in terms of treatments used and associated expected effects
[25, 26]. Annual transition probabilities govern the pro-
gress of patients through the different simulated health
states linked to, and influenced by, patient demographics,
development of complications and other relevant variables.
Costs and utility weights are applied to the cohort in
each annual cycle. Outcomes include the number of life-
years, QALYs, costs, ICERs, and cumulative incidence of
complications and adverse events. The model provides the
option of selecting risk equations; the Swedish NDR
macrovascular equations [25] and the UKPDS-OM2 (UK
Prospective Diabetes Study Outcomes Model 2) mortality
risk equations [26] were chosen to reflect the Swedish
patient population. The model also includes separate
analyses for men and women and for smokers and non-
smokers, since the risk equations for these groups differ.
Non-smoking men were selected for the base-case analysis,
whereas sensitivity analyses were performed for the other
populations.
2.2 Comparators and Clinical Data
Comparators used in the cost-effectiveness analysis inclu-
ded a number of options for treatment intensification: up-
titration of basal insulin, basal–bolus insulin and GLP-1
receptor agonist added to basal insulin. The comparators
for up-titrated basal insulin were insulin glargine and NPH
insulin; the comparators for basal–bolus regimens were
insulin aspart added to both insulin glargine and NPH
insulin; and the comparators for the GLP-1 analogue were
liraglutide added to both insulin glargine and NPH insulin.
As the clinical study programme for IDegLira (Xulto-
phy) has reported only two comparative studies with
insulin degludec and liraglutide in patients with diabetes
uncontrolled with basal insulin (DUALTM II and DUALTM V)
but none with a basal–bolus regimen or combination of
GLP-1 receptor analogue and basal insulin, clinical data for
the cost-effectiveness evaluation were based on an indirect
treatment comparison (ITC) [27] of several studies
[27–32]. For information on the ITC methodology, please
see the ESM. Clinical data for all NPH insulin comparisons
in the analysis were assumed to be the same as for insulin
glargine, with the exception of the hypoglycaemia rates for
up-titrated NPH insulin only (hypoglycaemia levels for up-
titrated insulin glargine and NPH insulin were based on the
results of a separate meta-analysis) [33]. Given the lack of
data comparing hypoglycaemia levels between insulin
glargine and NPH insulin in combination with insulin
aspart or liraglutide, we conservatively assumed that these
hypoglycaemia rates are the same (Table 1).
Treatment intensification was based on the assumption
that treatment will be intensified when the HbA1c level
reaches 8.8%. This figure represents the average HbA1c
level at which investigators in the DUALTM II study
deemed patients suitable for intensification and is in line
with national treatment guidelines for diabetes that rec-
ommend patients with HbA1c levels[8.6% be prioritised
for intensification [34]. The same HbA1c level was used as
baseline both for initiating IDegLira and for switching to
basal–bolus therapy. Additionally, we assumed that
patients with a blood pressure of C140 mmHg would
receive an angiotensin-converting enzyme (ACE) inhibitor
(20 mg daily) as per diabetes treatment guidelines [35],
which would lower blood pressure by 5%, adjunct statins
(40 mg daily) once their serum lipids (low-density
lipoprotein [LDL]) reached 2.5 mmol/l and a fibrate once
their triglycerides reached 1.7 mmol/l.
Data from DUALTM II [28] were used for baseline
values for the model (Table 2). Additional baseline vari-
ables such as heart rate, white blood cells, and estimated
glomerular filtration rate (eGFR) were obtained from the
UKPDS-OM2 study [26]. The prevalence of cardiovascular
complications (with the exception of atrial fibrillation) was
obtained from the NDR cohort on which the risk equations
are based (personal communication; Ali Kiadaliri, Lund
University).
Efficacy endpoints were taken from the ITC [27] and
only included clinical endpoints where there was a statis-
tically significant difference between treatments. Other-
wise, the comparator was assumed to be as effective as
IDegLira (Table 1).
2.3 Costs
All costs, except drugs and consumables, are expressed as
SEK, year 2013 values, and adjusted for inflation using the
Swedish healthcare consumer price index yields as neces-
sary [36] (Table S1 in the ESM). The current analysis was
conducted in 2014 so we used the 2013 costing year. We
acknowledge the costing year might affect the results of the
analysis; however, we believe that expressing costs in SEK,
year 2013 values, does not affect the results significantly
because of the low inflation rate (0.7%) [36] in 2013 in
Sweden compared with 2016. Prices of drugs and con-
sumables were obtained from the TLV price database
(Table 3) [37].
The drug costs were based on pharmacy retail prices
(PRPs) in September 2014, and daily doses from the clin-
ical studies were used for IDegLira and its comparators.
The price of IDegLira is billed per dose step rather than
unit, which accounted for varying doses of insulin degludec
and liraglutide. Doses reported by Freemantle et al. [27]
were adjusted using statistical modelling to account for
differences in baseline characteristics between the study
cohorts. We assumed the dose of human insulin was the
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same as that of insulin glargine for all treatment arms with
a basal insulin when dosing once daily, given there has
been no documentation of any difference in dose and NPH
insulin is more likely to be administered twice daily with
an associated increase in dose [38].
All patients were assumed to be using metformin
1500 mg daily (highest tolerable dose) as an adjuvant to
the study medication as per diabetes treatment guidelines
[35]. Patients who received IDegLira, basal insulin or GLP-
1 added to basal insulin were assumed to perform one
blood glucose test per day, whereas patients receiving
basal–bolus regimens were assumed to perform four tests
daily. The number of blood glucose tests for each com-
parator was based on the minimum number of daily doses
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125.05 285.53*e 344.01*e 794.63* 124.46e 124.46e
Data are presented as mean (standard error)
D difference operator, BMI body mass index, HbA1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, IDegLira insulin
degludec liraglutide, LDL-C low-density lipoprotein cholesterol, NPH neutral protamine Hagedorn, PYs patient-years, SBP systolic blood
pressure, TC total cholesterol
* Statistically significant difference
a Clinical data regarding NPH insulin were conservatively assumed to be the same as for insulin glargine, with the exception of the hypo-
glycaemia rate
b As no studies have documented the difference in hypoglycaemia between insulin glargine and NPH insulin as part of a basal–bolus regimen,
we made a conservative assumption that the rate of hypoglycaemia for these treatments is the same. All other clinical data regarding NPH insulin
were conservatively assumed to be the same as those for insulin glargine
c Given that the clinical trials included in the indirect treatment compared IDegLira vs. liraglutide 1.8 mg, data for this dose were applied to
liraglutide 1.2 mg (more common dose in Sweden). Thus, we conservatively assumed the two doses have equivalent efficacy but only used the
price of the lower dose in the base-case analysis
d Cholesterol was converted from mg/dl to mmol/l using the formula [mmol/l = (mg/dl)/39]. Triglycerides have been converted from mg/dl to
mmol/l using the formula [mmol/l = (mg/dl)/89]
e Relative difference between insulin glargine and NPH insulin with respect to hypoglycaemia [27]
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required, i.e. one daily dose for IDegLira, basal insulin or
GLP-1 added to basal insulin and four daily doses for
basal–bolus insulin [35]. The unit cost of blood glucose
tests (SEK2.58) was obtained by adding up the prices (PRP
excluding value-added tax [VAT]) of the test strips using
the lowest price per piece and the lancets using the lowest
price according to the TLV price database [37].
Costs for an episode of severe hypoglycaemia were
based on figures from a study by Jo¨nsson et al. [13]. A
weighted mean cost (SEK1970, year 2013 values) for each
severe hypoglycaemia episode was calcualted using the
conversion rate €1 = SEK9.21, August 2006 values, and
adjusting for inflation. For mild hypoglycaemia, we used
data from Geelhoed-duijvestijn et al. [39], which enabled
calculation of the cost per mild hypoglycaemia episode at
SEK50.
The costs of diabetes-related complications (e.g. heart
failure, stroke, etc.) were identified from a published
Swedish cost-effectiveness analysis (Table S1 in the ESM)
[40] and adjusted for inflation to 2013 monetary values.
The analysis also included indirect costs of diabetes-related
complications. Working age was assumed to be
20–65 years, with an average annual income of
SEK394,800 for men and SEK340,800 for women [41]. A
working year was assumed to consist of 250 working days.
Data on sick days due to various diabetes complications
were obtained from a Danish registry data analysis that
comprised 34,882 patients with diabetes [42]. If we were
unable to determine the number of sick days, a conserva-
tive assumption was made that the number of sick days was
0. The health economic model does not differentiate
between sick days during the ‘first’ and ‘subsequent’ years
for each condition; however, this was reported in the
Danish study. We therefore used the ‘subsequent years’
values to ensure a conservative analysis, as these were
consistently lower. The analysis used a human capital
approach.
2.4 Utilities
Utility values for various diabetes-related complications
used in this cost-effectiveness analysis were derived from
published studies (Table 4). Utilities associated with
treatment complexity and utilities associated with the
short-term effects of changes in HbA1c levels were derived
from the results of a time trade-off (TTO) study carried out
in Sweden, Denmark and the UK [43]. The disutility of
blood glucose testing was obtained from a TTO study
carried out in Sweden, the UK and Canada [44]. For the
effect of weight loss, as measured by body mass index
(BMI), we used the lower of the utility values found in
published studies (-0.006) [45–47] for the main analysis
and the value from the TTO study (-0.021) in the sensi-
tivity analysis. Data on the extent to which patients’ per-
ceived utility is affected by hypoglycaemia episodes were
derived from results for Swedish patients with T2DM in an
extensive web-based TTO study [48, 49].
2.5 One-Way Sensitivity Analyses
As the base case used non-smoking men to model the cost
effectiveness of IDegLira, we performed sensitivity anal-
yses on patient characteristics with risk equations that
differ from those for non-smokers and men, i.e. smokers
and women. Various other characteristics, such as a base-
line HbA1c of 9% and a baseline BMI of 25 and 35 were
also modelled in sensitivity analyses to investigate their
effects on the cost effectiveness of IDegLira. Other sensi-
tivity analyses were performed for clinical endpoints
(HbA1c drift for GLP-1 of 0.08%, no difference in HbA1c,
no difference in HbA1c but different complexity of regi-
men, depending on the number of daily injections, half the
difference in HbA1c, no difference in BMI, no difference in
hypoglycaemia for insulin glargine/NPH insulin, lower
efficacy for liraglutide 1.2 mg), costs (healthcare perspec-
tive and using the price of a higher dose of liraglutide) and
patient utilities (impact of BMI using a utility value of
-0.021, no impact of complexity vs. basal–bolus). These
analyses and the rationale for undertaking them are out-
lined in Tables S2–S4 in the ESM.
2.6 Probabilistic Sensitivity Analyses
Probabilistic sensitivity analyses (PSAs) were conducted to
assess the cost effectiveness of IDegLira when uncertainty
Table 2 Baseline values of patients assigned to the IDegLira treat-
ment arm used for the cost-effectiveness analysis from DUALTM II
(NN9068-3912) [20]
Demographics and risk factors Mean (standard deviation)
Age at presentation (years) 57.2 (9.7)
Duration of diabetes (years) 10.6 (6.5)
HbA1c, % 8.8 (0.7)
SBP (mmHg) 132.4 (15.1)
TC (mmol/l)a 4.67 (1.21)
LDL-C (mmol/l)a 2.58 (0.96)
HDL-C (mmol/l)a 1.16 (0.31)
Triglycerides (mmol/l)a 2.18 (2.10)
BMI (kg/m2) 33.7 (5.7)
BMI body mass index, HbA1c glycated haemoglobin, HDL-C high-
density lipoprotein cholesterol, IDegLira insulin degludec liraglutide,
LDL-C low-density lipoprotein cholesterol, TC total cholesterol, SBP
systolic blood pressure
a Cholesterol was converted from mg/dL to mmol/L using the for-
mula [mmol/l = (mg/dl)/39]. Triglycerides were converted from mg/
dL to mmol/L using the formula [mmol/l = (mg/dl)/89]
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of input variables were examined simultaneously. The
absolute treatment effect on the HbA1c level, the annual
absolute drift of the HbA1c level, HbA1c, initial absolute
treatment effects on other biomarker levels and absolute
drift of the other biomarker levels were varied using a
normal distribution. To avoid negative values, event rates
for hypoglycemia and other adverse events were varied
using a log-normal distribution. Standard errors (SEs) of
variables were used in the analyses where available
(Table S3 in the ESM). If the SE of a variable was not
available, assumptions were made (Table S3 in the ESM).
All assumptions were made in consultation with TLV in
conjunction with the reimbursement application of IDe-
gLira. Each simulation employed 500 iterations.
3 Results
Table 5 outlines the cost per QALY gained in each of the
main analyses, rounded to the nearest full hundred. All
results are below SEK70,100 per QALY, suggesting that
IDegLira is a cost-effective treatment option compared
with the other six treatment options for patients with
T2DM uncontrolled with basal insulin treatments.
3.1 IDegLira Versus Basal Insulin
The analysis of IDegLira versus up-titrated basal insulin in
patients who had not achieved HbA1c control with basal
insulin showed a QALY difference of 0.97 compared with














added to NPH insulin
Treatments
IDegLira 50.42 – – – – – –
Liraglutide – – – – – 33.36c 33.36c
Basal
insulin
– 22.26 9.98 24.57 11.02 12.97 5.81
Prandial
insulin
– – – 12.80 12.80 – –
Metformin 0.66 0.66 0.66 0.66 0.66 0.66 0.66
Consumables
Needlesb,d 0.69 0.69 0.69 2.76e 2.76e 1.38f 1.38f
Test stripsg 2.34 2.34 2.34 9.35h 9.35h 2.34 2.34








19,850 9565 5080 18,689 13,722 18,608 15,994
IDegLira insulin degludec liraglutide, NPH neutral protamine Hagedorn, PRP pharmacy retail price, SEK Swedish krona, TLV Tandva˚rds- och
la¨kemedelsfo¨rma˚nsverket (Swedish Dental and Pharmaceutical Benefits Agency), VAT value-added tax
a Prices were obtained from the TLV price database on 5 September 2014
b The cost of needles were conservatively based on the PRP excluding VAT for the lowest-priced needles on the TLV website [34]; use was
based on the number of injections
c Expressed as the cost of liraglutide 1.2 mg calculated based on the PRP (TLV) of liraglutide 54 mg (Victoza)
d Expressed as the cost per unit calculated based on the PRP (TLV) of a 100 pack of I-Fine S 6 mm 31 G needles (NordicInfu Care AB) unless
otherwise stated
e Expressed as the cost of 4 units calculated based on the PRP (TLV) of a 100 pack of I-Fine S 6 mm 31 G needles (NordicInfu Care AB)
f Expressed as the cost of 2 units calculated based on the PRP (TLV) of a 100 pack of I-Fine S 6 mm 31 G needles (NordicInfu Care AB)
g Expressed as the cost per unit calculated based on the PRP (TLV) of a 50 pack of Wellion Luna test strips (Medtrust Sweden AB) unless
otherwise stated
h Expressed as the cost of 4 units calculated based on the PRP (TLV) of a 50 pack of Wellion Luna test strips (Medtrust Sweden AB)
i Expressed as the cost per unit calculated based on the PRP (TLV) of a 200 pack of lancets (NordicInfu Care AB) unless otherwise stated
j Expressed as the cost of 4 units calculated based on the PRP (TLV) of a 200 pack of lancets (NordicInfu Care AB)
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both insulin glargine and NPH insulin. IDegLira was more
expensive, as shown by differences in treatment costs of
SEK65,000 and 106,000 compared with insulin glargine
and NPH insulin, respectively. However, the cost of com-
plications was higher in the groups receiving up-titrated
basal insulin, which meant the overall cost difference
dropped to SEK28,000 and 68,000 compared with insulin
glargine and NPH insulin, respectively. The greatest sav-
ings with IDegLira were seen in the costs of nephropathy
and stroke. Patients using IDegLira switched to basal–
bolus therapy after 12 years in the model simulation. The
corresponding period in the basal insulin arm was 7 years.
These results give an ICER (cost per QALY gained) of
SEK28,000 compared with insulin glargine and
SEK70,000 compared with NPH insulin, with the only
differences between insulin glargine and NPH insulin being
the price and rate of hypoglycaemia.
The only sensitivity analysis that had any appreciable
effect on the result were those that involved HbA1c. The
analysis in which the HbA1c drift during treatment with




utilities used in the analysis
Characteristic Utility score References
Demographics
Diabetes diagnosis 0.817 [41]
Age (per 10 years) -0.024 [42]
Sex (female) -0.056 [41]
Duration of diabetes (per 10 years) -0.010 [41]
Clinical factors
HbA1c (%) -0.025 [55]
BMI (kg/m2) -0.006 [41, 42]
Mild daytime hypoglycaemia -0.00449 [44, 45]
Severe daytime hypoglycaemia -0.05250 [44, 45]
Impact of treatment complexity
One injection/day vs. two injections at the same
time/day (IDegLira vs. GLP-1 added to basal insulin)
0.015a [55]
One injection/day vs. four injections/day including




Non-proliferative retinopathy -0.012 [41]
Proliferative retinopathy -0.012 [41]
Macular oedema -0.012 [41]
Severe visual impairment -0.057 [41]
Neuropathy
Symptomatic neuropathy -0.084 [42]




Clinical nephropathy -0.048 [42]
Kidney disease, uraemia stage -0.175 [42]
Macrovascular complications
Ischaemic heart disease -0.052 [41]
Myocardial infarction -0.022 [41]
Stroke -0.111 [41]
Heart failure -0.082 [41]
BMI body mass index, GLP-1 glucagon-like peptide-1, HbA1c glycated haemoglobin, IDegLira insulin
degludec liraglutide, kg kilogrammes
a This difference was not significant in the analysis of Swedish patients and has therefore not been included
in the analyses. However, the difference was significant in the analysis of Danish and British subjects,
which included more subjects
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GLP-1 receptor analogue was set to 0.08% [50] instead of
0.15% [51, 52] allowed patients to continue receiving this
treatment for 21 years—instead of 12 years as in the main
analysis—before triggering the switch to basal–bolus. This
suggests IDegLira is dominant compared with insulin
glargine, and the overall cost per QALY dropped to
SEK39,000 compared with NPH insulin (Table S4 in the
ESM). If the difference in HbA1c reduction was ignored
altogether, the cost per QALY rose to SEK332,000 and
484,000, respectively. If, instead, the difference in HbA1c
reduction was assumed to be halved, the cost per QALY
came to SEK92,000 and 156,000, respectively.
The cost-effectiveness acceptability curve resulting
from the PSA of IDegLira versus NPH insulin and insulin
glargine (Figs. S2 and S3 in the ESM, respectively) shows
that, for a willingness-to-pay threshold of SEK300,000 per
QALY, the probability of IDegLira being cost effective
was 100% in both cases.
3.2 IDegLira Versus Basal–Bolus Insulin
Analyses of IDegLira versus basal–bolus, in patients with
T2DM uncontrolled with basal insulin therapy, were per-
formed with insulin aspart added on to both insulin glar-
gine and NPH insulin as basal insulins. The only difference
between these analyses was the price of the basal insulin,
assuming identical clinical effects. Patients using IDegLira
switched to basal–bolus therapy after 12 years. Since the
comparator treatment was basal–bolus therapy from the
start, patients in this arm continued to receive this treat-
ment throughout the duration of the analysis period.
The difference in QALYs was 2.13 when compared with
either insulin glargine or NPH insulin and consisted mainly
of a difference in quality of life as a result of fewer com-
plications, fewer hypoglycaemia episodes and less complex
treatment. The cost of medication (treatment cost) was
SEK18,000 higher with IDegLira than with insulin aspart
added to insulin glargine. However, the cost of long-term
complications was considerably higher with basal–bolus
therapy, which resulted in the overall cost associated with
IDegLira being SEK115,000 lower than with insulin aspart
added to insulin glargine, suggesting that the IDegLira
treatment was dominant (superior in terms of QALYs and
cheaper). The treatment cost was SEK60,000 higher with
IDegLira than with insulin aspart added to NPH insulin.
However, when accounting for the cost of complications,
the overall cost of IDegLira was SEK47,000 lower, with
IDegLira again being dominant.
Similar results were seen in all sensitivity analyses
(Table S4 in the ESM). Furthermore, the cost-effectiveness
acceptability curves for insulin aspart added to NPH insulin
(Fig. S4 in the ESM) and insulin aspart added to insulin
glargine (Fig. S5 in the ESM) show that, at a willingness-
to-pay threshold of SEK300,000 per QALY gained, the
probability that IDegLira is cost effective was 100% in
both cases.
3.3 IDegLira Versus Basal Insulin 1 Liraglutide
The analyses of IDegLira versus liraglutide 1.2 mg added
to basal insulin in patients with T2DM uncontrolled with
basal insulin were performed with both insulin glargine and
NPH insulin as the basal insulin comparator. The lower
dose of liraglutide 1.2 mg instead of 1.8 mg was used in
the model as it is more common in Sweden than the higher
dose. The difference in QALYs was 0.40 and consisted
mainly of a difference in quality of life due to fewer
complications, fewer hypoglycaemia episodes and less
complex treatment in the IDegLira group. Patients using
IDegLira switched treatment after 12 years, whereas
patients treated with liraglutide added to basal insulin
switched after 9 years in the model simulation.
In the analysis versus liraglutide added to insulin glar-
gine, the overall cost associated with IDegLira was
SEK3500 lower than with liraglutide added to insulin
glargine, suggesting that IDegLira treatment was dominant.
The ICER was SEK60,000 in the analysis versus liraglutide
added to NPH insulin.
Table 5 Summary of base-case
analysis results in costs
(Swedish krona) per quality-
adjusted life-year gained for
each comparatora
Treatment A Treatment B D Costs D QALYs Cost per QALY
IDegLira Insulin glargine 27,700 0.97 28,400
IDegLira NPH insulin 68,400 0.97 70,100
IDegLira Insulin aspart added to insulin glargine –115,200 2.14 Dominant
IDegLira Insulin aspart added to NPH insulin –47,200 2.14 Dominant
IDegLira Liraglutide 1.2 mg added to insulin glargine –3500 0.40 Dominant
IDegLira Liraglutide 1.2 mg added to NPH insulin 24,000 0.40 60,000
D difference operator, IDegLira insulin degludec liraglutide, NPH neutral protamine Hagedorn, QALY
quality-adjusted life-year, SEK Swedish krona
a At the time of manuscript submission, the SEK to  and SEK to € exchange rate was 0.086918 and
0.102420, respectively. For instance, SEK1000 = 86.91 or €1024.20 [60]
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The majority of the sensitivity analyses provided results
that were only marginally different from those of the main
analysis. Ignoring the difference in HbA1c meant there was
no efficacy difference between treatments, whereas the
price of the liraglutide added to basal insulin was lower.
When we assumed the difference in HbA1c reduction was
half of that reported in the ITC, the cost per QALY came to
SEK30,000 and 149,000, respectively, suggesting that
HbA1c reduction is the main driver of the results.
Where the difference in HbA1c was disregarded but the
non-significant complexity utility difference was included,
the cost per QALY was SEK79,000 and 247,000, respec-
tively, compared with liraglutide added to insulin glargine
and NPH insulin. In addition, a sensitivity analysis was
performed with the price of liraglutide 1.8 mg instead of
1.2 mg in the comparator arm. The rationale for this was
that the clinical comparison was based on the higher dose.
These analyses showed that IDegLira was dominant for
liraglutide added on to both NPH and insulin glargine
(Table S4 in the ESM).
PSAs further confirmed the results of the base case, with
IDegLira displaying a lower cost per QALY than liraglu-
tide added to NPH insulin (SEK55,654 vs. 60,000), while
still being dominant compared with liraglutide added to
insulin glargine. The cost-effectiveness acceptability
curves (Figs. S6 and S7 in the ESM) show that, for a
willingness-to-pay threshold of SEK300,000, the estimated
probability that IDegLira is cost effective compared with
liraglutide added to NPH insulin and liraglutide added to
insulin glargine was 99 and 100%, respectively.
4 Discussion
We have demonstrated that IDegLira may be a cost-ef-
fective treatment compared with the most commonly used
treatment options for patients with T2DM uncontrolled
with basal insulin. The analyses show that IDegLira is
either dominant or has a cost-per-QALY below
SEK70,100, which is deemed to be well below the will-
ingness-to-pay threshold in Sweden [23].
The difference in HbA1c reduction is driving the result
(as a reduction in HbA1c results in fewer complications and
associated costs), but even if the difference is only half of
that observed in the ITC, IDegLira remains cost effective
in all comparisons (the Swedish National Board of Health
and Welfare generally view an ICER of
SEK100,000–500,000 as moderate) [23].
To our knowledge, the model used here is the only
T2DM model developed for the Swedish population that
includes Swedish macrovascular risk functions, with the
majority of quality-of-life weights also being obtained
from Swedish patients with T2DM [24].
The utility values for severe and non-severe hypogly-
caemia used in the model are low and thus did not influence
the results of the analysis. The model also allows the
treatment to realistically follow disease progression. The
external validation of the model was tested by simulating
12 clinical trials (both interventional and non-interven-
tional) and comparing 167 predicted microvascular,
macrovascular and mortality outcomes with those observed
in the actual trials [24]. Moreover, the model has been used
for several analyses, both in health economic publications
[40, 45] and in the development of new national diabetes
guidelines [6].
The analyses were based on an ITC of clinical studies
[27] because, to date, the only clinical trials of IDegLira in
patients with diabetes uncontrolled with basal insulin
(DUALTM II and DUALTM V) are comparative studies of
insulin degludec and liraglutide. Only DUALTM II results
were included because the DUALTM V trial was ongoing at
the time of the ITC. Nonetheless, the results of the ITC
enabled a comprehensive analysis in which IDegLira was
compared with all relevant treatment options. The ITC was
performed according to best practice based on available
data. In the clinical studies included in the ITC, liraglutide
was used at a dose of 1.8 mg instead of 1.2 mg, which is
the more common dose in Sweden. Given the indirect
nature of such a comparative method, this could be con-
sidered a limitation of the economic evaluation. However,
considering the paucity of head-to-head clinical trial data,
these types of approaches have become increasingly
accepted and recommended by health technology assess-
ment bodies across Europe [22, 53–55]. Furthermore, the
results of the same ITC were used in a previous economic
evaluation of IDegLira in patients with diabetes uncon-
trolled with basal insulin in a UK setting [56]. The use of
clinical trial data, rather than observational real-world data,
can also be considered a limitation of the model. When
considering the stringent nature of clinical trials, it can be
assumed that the clinical benefits of IDegLira would not
fully translate in the real world due to non-adherence to
treatment. While there is no way of assessing how clinical
practice differs from a clinical trial setting in the absence of
observational data, it is possible that the benefits of IDe-
gLira might have been overestimated. Further limitations
associated with the ITC are discussed in detail in Free-
mantle et al. [27].
As with any economic evaluation of long-term chronic
diseases, another limitation of our analysis is the use of
short-term clinical data to simulate the course of the dis-
ease on a 40-year time horizon. However, in the absence of
long-term clinical data, the use of a simulation model based
on clinical assumptions and long-term risk equations is
arguably the most appropriate approach to assess the cost
effectiveness of IDegLira and inform healthcare decisions.
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While the use of assumptions in health economic mod-
elling tends to introduce a degree of uncertainty to the
analyses, we have tried to minimise this by performing
sensitivity analyses and, where possible, using conservative
assumptions. For instance, the clinical data for NPH insulin
were conservatively assumed to be the same as for insulin
glargine in all combinations apart from the hypoglycaemia
rates in the comparisons with up-titrated basal insulin only.
These hypoglycaemia rates were based on a meta-analysis
comparing hypoglycaemia rates of insulin glargine and
NPH insulin [33]. Because data comparing hypoglycaemia
levels between insulin glargine and NPH insulin in com-
bination with insulin aspart or liraglutide were lacking, we
conservatively assumed that the hypoglycaemia rates were
the same for these combinations. Therefore, the main dif-
ferentiating factor between these insulins in the analysis
was the lower cost of NPH insulin. As we used clinical data
from the ITC in our analyses, together with the prices of
the more common and cheaper insulin options, our analy-
ses are more conservative. Nonetheless, IDegLira was
either dominant or cost effective (i.e. the cost per QALY
was lower than SEK100,000) in all sensitivity analyses
versus all the comparators. Similar results were obtained
from a UK perspective using the IMS Health CORE Dia-
betes Model, where IDegLira was demonstrated to be cost
effective [56, 57], which further demonstrates the relia-
bility of the Swedish IHE Cohort Model of Type 2
Diabetes.
In our analysis, treatment intensification was based on
an assumption in which we endeavoured to reflect real
life. We assumed that treatment would be intensified at a
level where the physician and patient consider the
patient’s HbA1c to be too high. For this reason, we
deemed it logical to use the same HbA1c level both for
initiating IDegLira and later on for switching to basal–
bolus therapy.
Utility scores were largely based on studies performed
on Swedish patients with T2DM. Several of these utilities
have been used previously, whereas others (patient utility
relative to HbA1c reduction and treatment complexity,
respectively) were developed specifically for the purpose
of this study [58]. The utility score of HbA1c reduction we
used is very close to an equivalent score obtained for type 1
diabetes mellitus [59]. The utility score of treatment
complexity may seem high compared with basal–bolus
therapy; however, considering the extent to which such a
complex regimen impacts on the patient’s everyday life,
with four daily injections using two different pen devices
as well as constant planning of doses and meals, this is not
surprising. In addition, we performed a sensitivity analysis
in which this utility score was excluded, which showed that
its impact on the outcome was marginal and did not change
the overall conclusion.
5 Conclusion
Based on the present findings, ths study has demonstrated
that IDegLira may be cost effective for the treatment of
patients with T2DM that is uncontrolled with basal insulin
therapy in Sweden. In all analyses, where IDegLira was
compared with up-titrated basal insulin, basal–bolus insulin
or a GLP-1 agonist added to basal insulin, IDegLira was
either cost effective, with an ICER of SEK70,000 or lower
(vs. basal insulin up-titration or vs. adding GLP1 to basal
insulin), or both more effective and cost saving (vs. basal–
bolus regimens). Sensitivity analyses show that the results
are stable and driven by the difference in HbA1c reduction
between treatments.
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